STOCK TITAN

PaxMedica Inc - PXMD STOCK NEWS

Welcome to our dedicated news page for PaxMedica (Ticker: PXMD), a resource for investors and traders seeking the latest updates and insights on PaxMedica.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PaxMedica's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PaxMedica's position in the market.

Rhea-AI Summary
PaxMedica, Inc. (NASDAQ:PXMD) announced the release of a Fireside Chat video featuring Chairman and CEO Howard Weisman, covering regulatory updates, financial boost, strategic acquisition, clinical trials progress, business efficiency, and future vision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
-
Rhea-AI Summary
PaxMedica, a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the closing of its public offering of 5,384,615 shares of common stock and warrants, generating approximately $7.0 million in gross proceeds. The net proceeds will be used to repay outstanding debt and advance development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
Rhea-AI Summary
PaxMedica, Inc. (NASDAQ:PXMD) Announces Pricing of Public Offering of Common Stock and Warrants at $1.30 per Share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44%
Tags
offering
Rhea-AI Summary
PaxMedica, Inc. (NASDAQ: PXMD) announces its feature in a broadcast via NetworkNewsAudio, highlighting the completion of a type-B meeting with the FDA and positive results from its PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness. The company is encouraged by the FDA's feedback and is focused on expediting the final steps toward its NDA submission for PAX-101, expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.37%
Tags
none
-
Rhea-AI Summary
PaxMedica, Inc. (NASDAQ:PXMD) announced a comprehensive business update and financial results for the third quarter of 2023. Key achievements include progress in FDA Type-B meeting for NDA submission of PAX-101, completion of Phase III trials for Human African Trypanosomiasis, strategic acquisition of suramin research assets, and completion of commercial-scale development plan for PAX-101. CEO Howard Weisman highlighted the company's progress and financial report indicated $1.2 million in cash reserves with access to $14.4 million from an equity investment agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.53%
Tags
earnings
-
Rhea-AI Summary
PaxMedica, Inc. (NASDAQ:PXMD) announced the publication of research findings in the Annals of General Psychiatry. The study explored the potential of low-dose suramin intravenous infusions as an Autism Spectrum Disorder (ASD) treatment, showing statistically significant improvements in the Clinical Global Impressions-Improvement (CGI-I) scale among the 10 mg/kg suramin arm compared to the placebo group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.54%
Tags
clinical trial
Rhea-AI Summary
PaxMedica, a biopharmaceutical company, has engaged Bourne Partners to explore monetization of a Priority Review Voucher (PRV) for the treatment of African Sleeping Sickness. The engagement aims to enhance research and development efforts in neurologic disorders. PaxMedica has decreased the outstanding amount under its convertible note with Lind Global Partners II, LP from $3.68 million to $2.27 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.31%
Tags
none
-
Rhea-AI Summary
PaxMedica, a biopharmaceutical company specializing in neurological disorder treatments, has successfully acquired suramin research assets from Rediscovery Life Sciences. These assets will support PaxMedica's efforts to seek approval for PAX-101, a treatment for African Sleeping Sickness. The integration of this data will aid in the submission for the New Drug Application (NDA) and manufacturing production requirements are on track for the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.62%
Tags
acquisition
-
Rhea-AI Summary
PaxMedica, Inc. (Nasdaq: PXMD) has completed a 1-for-17 reverse stock split of its common stock. The split-adjusted common stock will begin trading on October 31, 2023, under the symbol 'PXMD'. Each 17 pre-split shares were combined into one post-split share, with no fractional shares issued. Shareholders will receive information from Computershare Trust Corporation, the transfer agent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1318.09%
Tags
none
Rhea-AI Summary
PaxMedica's manuscript on low dose suramin infusions for Autism Spectrum Disorder has been accepted for publication in the Annals of General Psychiatry. The research highlights the potential of this treatment and is a significant milestone for the company's dedication to innovative ASD treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.59%
Tags
none
PaxMedica Inc

Nasdaq:PXMD

PXMD Rankings

PXMD Stock Data

2.56M
1.99M
18.44%
3.61%
0.28%
Biotechnology
Healthcare
Link
United States
Tarrytown